The call for change was prompted by the results showing that bevacizumab (Avastin, Genentech) added to the current standard of care (SOC) pemetrexed and cisplatin — provides significantly longer overall survival (OS) vs the SOC when used first-line in patients with malignant pleural mesothelioma.
The new data come from the French Cooperative Thoracic Intergroup (IFCT) MAPS study, reported at an oral session at the American Society of Clinical Oncology (ASCO) 2015 annual meeting.
The triplet of pemetrexed, cisplatin, and bevacizumab is a new treatment paradigm for pleural mesothelioma patients eligible for bevacizumab not amenable to curative surgery, concluded lead author Gerard Zalcman, MD. Discussing these data at a Highlights of the Day session, Natasha Leighl, MD, from Princess Margaret Cancer Centre, Toronto, Canada, said that these data were “practice changing” for patients with mesothelioma.
[Article continues at original source]
Asbestos-Mesothelioma Case Evaluation Form
Free. Confidential. No Obligation.